This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical ...

According to the note, in response to the update, Bell Potter has retained its buy rating and $2.00 price target on the ASX ...

On May 9, argenx SE (NASDAQ:ARGX) reported that the U.S. Food and Drug Administration approved a label expansion for Vyvgart ...

Biotech stocks tied to cancer, autoimmune and rare disease therapies gain attention as M&A activity boosts sector sentiment.

METiS TechBio debuts on Hong Kong stock market as its CEO compares the drug design start-up to SpaceX for the pharmaceutical ...

Why Makary resigned: Makary stepped down after disputes with the Trump administration over flavored e-cigarettes, abortion drug policy, and inconsistent drug review decisions. Market's initial ...

Sudden resignation: Makary stepped down after disputes over flavored vape approvals, abortion pill reviews, and unpredictable drug decisions drew political and industry backlash. Market reaction: ...

While many transportation companies struggle when fuel prices rise, FedEx and J.B. Hunt are positioned to benefit from ...

Vanda Pharmaceuticals (VNDA) buy case: new drug approvals, pipeline, and growth catalysts vs. cash burn, losses, and neutral ...

May 13 (Reuters) - U.S. Food and Drug Administration Commissioner ⁠Dr. ⁠Marty Makary's departure comes as a positive ⁠move ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will ...

Dyadic International (NASDAQ:DYAI) reported first-quarter financial results on Wednesday. The transcript from the company's ...